Clinical Trials Directory

Trials / Unknown

UnknownNCT02640313

Molecular Imaging of Plaque Vulnerability

Molecular Imaging of Plaque Vulnerability Using 18F-choline PET-MRI in Carotid Artery Atherosclerosis Patients

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
14 (estimated)
Sponsor
Maastricht University Medical Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Accumulating data in the literature suggests that radiolabeled-choline (18F-choline) is a sensitive molecular tracer for PET imaging that is taken up in activated cells and, as such, is able to identify active inflammatory sites. The investigators hypothesize that 18F-choline is also highly taken up in vulnerable plaques in comparison to the stable ones.

Detailed description

Accumulation and subsequent activation of inflammatory cells in the atherosclerotic plaques play an essential role in transforming a stable plaque into a vulnerable plaque at risk to rupture. On this basis, the study aims to evaluate the diagnostic performance of 18F-choline PET in identifying ongoing inflammation within atherosclerotic plaques. The investigators hypothesize that 18F-choline PET is efficient in detecting intraplaque inflammation and identify vulnerable plaques that are prone to rupture in comparison to the stable ones. It is likely that by correlating the inflammatory status of an atherosclerotic plaque (on 18F-choline PET) with the presence of other vulnerable plaque features (on MR imaging) would be of high clinical relevance for clinical diagnosis of vulnerable plaques.

Conditions

Interventions

TypeNameDescription
DRUG18F-choline PET-MR imagingDynamic and static 18F-choline PET-MR imaging

Timeline

Start date
2015-12-01
Primary completion
2024-03-01
Completion
2024-03-01
First posted
2015-12-28
Last updated
2023-10-24

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT02640313. Inclusion in this directory is not an endorsement.

Molecular Imaging of Plaque Vulnerability (NCT02640313) · Clinical Trials Directory